BioGeometry is a pioneering company in the field of digital biology, specializing in the application of generative artificial intelligence (GenAI) to protein design and drug discovery. The company has developed advanced AI-driven platforms, such as GeoBiologics, which facilitate the design and optimization of antibodies through a closed-loop system that integrates both dry lab (AI modeling) and wet lab (experimental validation) processes. This innovative approach allows for the efficient identification of functional molecules, significantly reducing the time and costs associated with traditional drug development methods. BioGeometry's technology leverages atomic-level geometric deep learning models to enhance the success rates of antibody design, ultimately aiming to address the challenges faced in large-molecule drug manufacturing.

In collaboration with other biotechnology firms, such as Sanyou Bio, BioGeometry is working to create next-generation antibody drug discovery platforms that enhance the efficiency of research and development in the pharmaceutical industry. By combining their generative AI capabilities with Sanyou's extensive wet lab resources, the partnership aims to streamline the drug development process, improve candidate drug screening, and foster innovation in biologics. This synergy not only promotes a digital transformation in drug R&D but also positions BioGeometry as a leader in the integration of AI technologies within the biopharmaceutical sector, contributing to the advancement of new therapeutic solutions.

United States

BioGeometry is an AI-driven biotech dedicated to developing next-generation, programmable protein medicines. We aim to solve the high cost, long lead time, low success rate problems for traditional macromolecular theraputics through the combination of geometric deep learning, structural biology, immunology, and synthetic biology.
We enjoy talents from renowned pharmaceutical companies, top-tier AI and bio labs worldwide.

BioGeometry

Company Details